Syros Pharmaceuticals, Inc.
NASDAQ:SYRS
0.22 (USD) • At close December 26, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Syros Pharmaceuticals, Inc. |
Symbool | SYRS |
Munteenheid | USD |
Prijs | 0.216 |
Beurswaarde | 5,793,137 |
Dividendpercentage | 0% |
52-weken bereik | 0.183 - 8.17 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Nancy A. Simonian M.D. |
Website | https://www.syros.com |
An error occurred while fetching data.
Over Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)